Hints and tips:
Related Special Reports
...When Ken Frazier, another law school friend, was CEO of Merck and facing criticism for refusing to cut research budgets, Ogunlesi reassured him he was doing the right thing....
...“It is not at all clear that Merck is doing anything other than extending its monopoly power over the drug,” Warren said....
...“Pfizer is very good at selling but historically not renowned as having the R&D engine of a Merck or Lilly....
...and working conditions, as well as what it is doing on the ground and through third-party assurance firms to verify all this....
...With $19mn, he co-founded Alexandria in 1994, at age 47, as a developer and operator of those specialised properties....
...“This is a 2025 product — so they [Merck] can give investors some confidence about the growth rate of the business....
...J&J’s consumer business sells skin, beauty and healthcare brands such as Tylenol, Listerine and Neutrogena, which have helped establish it as one of America’s most trusted companies over more than a century...
...Regeneron, though, is hardly a mom-and-pop business. It has a market value of $60bn....
...Dan Mahony, who co-leads the healthcare business at Polar Capital, said it was “a bit weird” that it was not GSK, the UK’s largest vaccine maker, that stepped in to help with the UK’s homegrown vaccine....
...The unprecedented public stand by the prominent African-American executives positions voting rights as the next battleground on which business will be expected to take a stand....
...Since then, the costs of doing business during Covid-19 have throttled growth and profits, with billions spent on keeping Amazon’s reputation for fast delivery intact....
...Jana Hecker, a senior investment banker who acted as a financial adviser to former Wirecard boss Markus Braun has left her job at UniCredit following revelations about the business relationship....
...BioNTech needed to make money from its first product to plough back into the business....
...After a Saturday Zoom call featuring executives from Merck’s Ken Frazier to James Murdoch, formerly of Fox, chief executives have decided to co-ordinate their response....
...“In 2009-10, pharma companies were priced as if they were going to go out of business, as if they were never going to have a [new] drug again,” he says....
...David Constable will step down as a non-executive director of Rio Tinto at the end of this year to pursue his new role as chief executive of Fluor Corporation....
...So what are they doing here?” she asks....
...As one senior economic adviser to the Abe administration put it: the idea of a co-operative Japan Inc might — just about — work in the aftermath of a conventional domestic disaster such as an earthquake,...
...Stefan Oschmann, chief executive of Merck Group, the Dax listed life sciences company best known for a pharmaceuticals business that dates back to 1668, says what he worries about is “the Uberisation of...
...“It is the reality of doing business in the market,” he says. “These are the structures that exist.”...
...Merck and other leading immuno-oncology companies, including Roche and Bristol-Myers, have had considerable success when pairing their drugs with older medicines, such as chemotherapy and earlier versions...
...“This year was supposed to be the year of combos, but it hasn’t materialised as quickly or as robustly as anyone would have hoped.”...
...Over the past year I have had business leaders lament to me that no Wall Street analyst ever asks them about their efforts to tackle climate change; I have seen companies such as Merck and Johnson & Johnson...
...Multinationals’ growth slowed in recent years as Beijing pushed for price cuts to hundreds of branded off-patent drugs as a condition of adding them to state co-payment schemes....
...After many false starts over the past decade, David Gross-Loh, the co-head of Bain’s Asia business, says “allergy to private equity has more or less gone”....
International Edition